Seroatlas · Human Serome Atlas

IFNL1

Interferon lambda-1

Also known as: IFNL1_HUMAN, IL-29, IL29

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8IU54
Gene: IFNL1
Ensembl: ENSG00000182393
Chromosome: 19
Canonical length: 200 aa
Protein class: Predicted secreted proteins
Secretome location: Secreted to blood

OverviewNCBI Gene

This gene encodes a cytokine distantly related to type I interferons and the IL-10 family. This gene, interleukin 28A (IL28A), and interleukin 28B (IL28B) are three closely related cytokine genes that form a cytokine gene cluster on a chromosomal region mapped to 19q13. Expression of the cytokines encoded by the three genes can be induced by viral infection. All three cytokines have been shown to interact with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor, beta (IL10RB) and interleukin 28 receptor, alpha (IL28RA). [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

200 residues, UniProt reviewed canonical sequence.

>Q8IU54|IFNL1
     1  MAAAWTVVLV TLVLGLAVAG PVPTSKPTTT GKGCHIGRFK SLSPQELASF KKARDALEES
    61  LKLKNWSCSS PVFPGNWDLR LLQVRERPVA LEAELALTLK VLEAAAGPAL EDVLDQPLHT
   121  LHHILSQLQA CIQPQPTAGP RPRGRLHHWL HRLQEAPKKE SAGCLEASVT FNLFRLLTRD
   181  LKYVADGNLC LRTSTHPEST

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against IFNL1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.39
Highest tissue expression: 0.1 nTPM

Expression across tissuesHPA

Tissue

appendix: 0.1 nTPM
duodenum: 0.1 nTPM
lung: 0.1 nTPM
spleen: 0.1 nTPM
adipose tissue: 0 nTPM
adrenal gland: 0 nTPM

Single-cell type

cdc: 6.7 nCPM
nk-cells: 4.8 nCPM
innate lymphoid cells: 3.3 nCPM
t-cells: 2.3 nCPM
retinal amacrine cells: 0.7 nCPM
undifferentiated spermatogonia: 0.4 nCPM

Immune cell

NK-cell: 4.6 nTPM
MAIT T-cell: 2.8 nTPM
gdT-cell: 2.7 nTPM
memory CD8 T-cell: 2.7 nTPM
myeloid DC: 2.3 nTPM
naive CD8 T-cell: 1.4 nTPM

Brain region

cerebral cortex: 1.1 nTPM
hippocampal formation: 0.9 nTPM
amygdala: 0.8 nTPM
cerebellum: 0.7 nTPM
basal ganglia: 0.6 nTPM
white matter: 0.6 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.52
gnomAD pLI: 0
gnomAD missense Z: -0.12
DepMap mean gene effect: -0.04
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

cytokine activity
signaling receptor binding
interleukin-28 receptor binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads IFNL1 as an antibody target. Whether an autoantibody or antibody against IFNL1 could matter depends on whether native IFNL1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

IFNL1 is annotated as secreted, so native IFNL1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label IFNL1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...